...
首页> 外文期刊>Radiation oncology >Definitive radiotherapy for early (T1-T2) Glottic Squamous cell carcinoma: a 20 year Cleveland clinic experience
【24h】

Definitive radiotherapy for early (T1-T2) Glottic Squamous cell carcinoma: a 20 year Cleveland clinic experience

机译:明确放疗早期(T1-T2)喇叭鳞状细胞癌:20年克利夫兰诊所经验

获取原文

摘要

Purpose To report our 20 yr experience of definitive radiotherapy for early glottic squamous cell carcinoma (SCC). Methods and materials Radiation records of 141 patients were retrospectively evaluated for patient, tumor, and treatment characteristics. Cox proportional hazard models were used to perform univariate (UVA) and multivariate analyses (MVA). Cause specific survival (CSS) and overall survival (OS) were plotted using cumulative incidence and Kaplan-Meir curves, respectively. Results Of the 91% patients that presented with impaired voice, 73% noted significant improvement. Chronic laryngeal edema and dysphagia were noted in 18% and 7%, respectively. The five year LC was 94% (T1a), 83% (T1b), 87% (T2a), 65% (T2b); the ten year LC was 89% (T1a), 83% (T1b), 87% (T2a), and 53% (T2b). The cumulative incidence of death due to larynx cancer at 10 yrs was 5.5%, respectively. On MVA, T-stage, heavy alcohol consumption during treatment, and used of weighted fields were predictive for poor outcome (p < 0.05). The five year CSS and OS was 95.9% and 76.8%, respectively. Conclusions Definitive radiotherapy provides excellent LC and CSS for early glottis carcinoma, with excellent voice preservation and minimal long term toxicity. Alternative management strategies should be pursued for T2b glottis carcinomas.
机译:目的,报告我们的早期喇叭鳞状细胞癌(SCC)的最终放射疗法的20年代经验。患者,肿瘤和治疗特征回顾性评估141名患者的方法和材料辐射记录。 Cox比例危险模型用于执行单变量(UVA)和多变量分析(MVA)。使用累积发病率和Kaplan-Meir曲线分别绘制特异性存活(CSS)和整体存活(OS)。 91%患者出现障碍患者的91%,73%有显着改善。慢性喉水肿和吞咽症分别以18%和7%指出。五年LC为94%(T1A),83%(T1B),87%(T2A),65%(T2B);十年LC为89%(T1A),83%(T1B),87%(T2A)和53%(T2B)。由于喉癌为10年的喉癌的累积发生率分别为5.5%。在治疗期间的MVA,T-阶段,重质醇消耗,并使用加权场的预测结果差(P <0.05)。五年CSS和OS分别为95.9%和76.8%。结论明确放疗为早期的最佳LC和CSS提供优异的LC和CSS,具有优异的语音保存和最小的长期毒性。应追究替代管理策略,以追求T2B发光癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号